$VYCO
Vycor Medical Inc Stock $vyco

$vyco Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-K Financial Statement

#000149315223012257 Filed on April 14, 2023

Income Statement

Concept	2023 Q2	2022 Q4	2022
Revenue	$482.8K	$271.3K	$1.223M
YoY Change	47.22%	-0.9%	-12.2%
Cost Of Revenue	$39.80K	$37.15K	$140.6K
YoY Change	42.72%	16.9%	4.39%
Gross Profit	$443.0K	$234.1K	$1.082M
YoY Change	47.64%	-3.24%	-13.98%
Gross Profit Margin	91.76%	86.3%	88.5%
Selling, General & Admin	$324.5K	$310.9K	$1.331M
YoY Change	-9.79%	-18.74%	-17.51%
% of Gross Profit	73.26%	132.81%	122.94%
Research & Development	$7.550K	$0.00
YoY Change		-100.0%
% of Gross Profit	1.7%	0.0%
Depreciation & Amortization	$15.07K	$15.33K	$61.40K
YoY Change	0.13%	-13.73%	-10.26%
% of Gross Profit	3.4%	6.55%	5.67%
Operating Expenses	$346.5K	$325.3K	$1.389M
YoY Change	-7.47%	-19.9%	-18.02%
Operating Profit	$96.52K	-$91.20K	-$306.5K
YoY Change	-229.78%	-44.46%	-29.69%
Interest Expense	-$25.73K	-$24.68K	-$93.19K
YoY Change	10.19%	12.69%	4.13%
% of Operating Profit	-26.66%
Other Income/Expense, Net	-$25.73K		-$93.19K
YoY Change	10.18%
Pretax Income	$70.79K	-$115.9K	-$399.7K
YoY Change	-172.44%	-37.74%	-2.09%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	$68.41K	-$116.6K	-$404.9K
YoY Change	-169.09%	-37.69%	-7.06%
Net Earnings / Revenue	14.17%	-42.97%	-33.11%
Basic Earnings Per Share	$0.00		-$0.02
Diluted Earnings Per Share	$0.00	$0.00	-$0.02
COMMON SHARES
Basic Shares Outstanding	32.63M shares	32.53M shares	31.71M shares
Diluted Shares Outstanding	37.47M shares		31.71M shares

Balance Sheet

Concept	2023 Q2	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$53.40K	$37.04K	$37.04K
YoY Change	22.42%	-59.27%	-59.27%
Cash & Equivalents	$53.40K	$37.04K
Short-Term Investments
Other Short-Term Assets	$62.93K	$75.65K	$75.65K
YoY Change	14.42%	20.37%	20.37%
Inventory	$219.5K	$248.9K	$248.9K
Prepaid Expenses
Receivables	$282.6K	$156.2K	$156.2K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$618.4K	$517.8K	$517.8K
YoY Change	20.59%	6.23%	6.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$272.8K	$303.8K	$336.4K
YoY Change	-18.56%	-16.18%	-23.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$6.000K	$6.000K	$6.000K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$287.1K	$342.4K	$342.4K
YoY Change	-27.76%	-23.56%	-23.56%
TOTAL ASSETS
Total Short-Term Assets	$618.4K	$517.8K	$517.8K
Total Long-Term Assets	$287.1K	$342.4K	$342.4K
Total Assets	$905.4K	$860.2K	$860.2K
YoY Change	-0.52%	-8.04%	-8.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$123.4K	$200.0K	$200.0K
YoY Change	-16.4%	-12.15%	-12.16%
Accrued Expenses	$2.860M	$2.638M	$2.638M
YoY Change	14.1%	15.57%	15.57%
Deferred Revenue
YoY Change
Short-Term Debt	$796.8K	$818.1K	$818.1K
YoY Change	13.34%	27.79%	27.79%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.779M	$3.655M	$3.655M
YoY Change	12.62%	16.03%	16.03%
LONG-TERM LIABILITIES
Long-Term Debt	$144.6K	$146.3K	$146.3K
YoY Change	-2.22%	-2.5%	-2.5%
Other Long-Term Liabilities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Liabilities	$144.6K	$146.3K	$146.3K
YoY Change	-6.04%	-19.01%	-19.01%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.779M	$3.655M	$3.655M
Total Long-Term Liabilities	$144.6K	$146.3K	$146.3K
Total Liabilities	$3.924M	$3.801M	$3.801M
YoY Change	11.8%	14.13%	14.13%
SHAREHOLDERS EQUITY
Retained Earnings	-$32.51M	-$32.43M
YoY Change	1.5%	2.3%
Common Stock	$3.273K	$3.263K
YoY Change	1.99%	5.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.033K	$1.033K
YoY Change	0.0%	0.0%
Treasury Stock Shares		103.3K shares
Shareholders Equity	-$3.018M	-$2.941M	-$2.941M
YoY Change
Total Liabilities & Shareholders Equity	$905.4K	$860.2K	$860.2K
YoY Change	-0.52%	-8.04%	-8.04%

Cashflow Statement

Concept	2023 Q2	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	$68.41K	-$116.6K	-$404.9K
YoY Change	-169.09%	-37.69%	-7.06%
Depreciation, Depletion And Amortization	$15.07K	$15.33K	$61.40K
YoY Change	0.13%	-13.73%	-10.26%
Cash From Operating Activities	$13.33K	-$33.36K	-$217.0K
YoY Change	-147.37%	-206.07%	-1115.52%
INVESTING ACTIVITIES
Capital Expenditures		-$320.00	$2.780K
YoY Change		-203.23%	-107.24%
Acquisitions
YoY Change
Other Investing Activities	$250.00
YoY Change
Cash From Investing Activities	$250.00	$320.00	-$2.780K
YoY Change	-107.81%	3.23%	-92.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-7.980K	37.50K	$165.9K
YoY Change	41.99%	-293.4%	167.78%
NET CHANGE
Cash From Operating Activities	13.33K	-33.36K	-$217.0K
Cash From Investing Activities	250.0	320.0	-$2.780K
Cash From Financing Activities	-7.980K	37.50K	$165.9K
Net Change In Cash	5.600K	4.460K	-$53.91K
YoY Change	-115.15%	-63.95%	-219.95%
FREE CASH FLOW
Cash From Operating Activities	$13.33K	-$33.36K	-$217.0K
Capital Expenditures		-$320.00	$2.780K
Free Cash Flow		-$33.04K	-$219.8K
YoY Change		-206.1%	-467.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001424768
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	VYCO	Forgiveness Of Debt Paycheck Protection Program ForgivenessOfDebtPaycheckProtectionProgram		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
CY2022	VYCO	Forgiveness Of Debt Paycheck Protection Program ForgivenessOfDebtPaycheckProtectionProgram		usd
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt		usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue		usd
CY2021	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue		usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold		usd
CY2021	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold		usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss		usd
CY2021	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss		usd
CY2022	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation		usd
CY2021	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation		usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber		shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber		shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-34932
CY2022	dei	Entity Registrant Name EntityRegistrantName	VYCOR MEDICAL, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-3369218
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	951 Broken Sound Boulevard
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	320 Boca Raton
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33487
CY2022	dei	City Area Code CityAreaCode	561
CY2022	dei	Local Phone Number LocalPhoneNumber	558-2020
CY2022	dei	Security12b Title Security12bTitle	Common Stock
CY2022	dei	Trading Symbol TradingSymbol	VYCO
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	1667743	usd
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	32628835	shares
CY2022	dei	Auditor Name AuditorName	Prager Metis CPAs, LLC
CY2022	dei	Auditor Location AuditorLocation	Hackensack, New Jersey
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37035	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	90941	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	156204	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	126096	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	248874	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	207521	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	74438	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	62473	usd
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	1212	usd
CY2021Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	380	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	517763	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	487411	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	303770	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	362393	usd
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	6000	usd
CY2021Q4	us-gaap	Security Deposit SecurityDeposit	6000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	32645	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	79560	usd
CY2022Q4	VYCO	Intangible And Other Asset Total IntangibleAndOtherAssetTotal	38645	usd
CY2021Q4	VYCO	Intangible And Other Asset Total IntangibleAndOtherAssetTotal	85560	usd
CY2022Q4	us-gaap	Assets Assets	860178	usd
CY2021Q4	us-gaap	Assets Assets	935364	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	200044	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	227720	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	424897	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	380479	usd
CY2022Q4	VYCO	Accrued Interest Related Party AccruedInterestRelatedParty	146007	usd
CY2021Q4	VYCO	Accrued Interest Related Party AccruedInterestRelatedParty	106444	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	91352	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	126959	usd
CY2022Q4	us-gaap	Due To Other Related Parties Classified Current DueToOtherRelatedPartiesClassifiedCurrent	1946220	usd
CY2021Q4	us-gaap	Due To Other Related Parties Classified Current DueToOtherRelatedPartiesClassifiedCurrent	1621850	usd
CY2022Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	324711	usd
CY2021Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	319329	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	493373	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	320873	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	29591	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	46915	usd
CY2022Q4	VYCO	Liabilities Of Disposal Groups Including Discontinued Operation Current LiabilitiesOfDisposalGroupsIncludingDiscontinuedOperationCurrent	-1399	usd
CY2021Q4	VYCO	Liabilities Of Disposal Groups Including Discontinued Operation Current LiabilitiesOfDisposalGroupsIncludingDiscontinuedOperationCurrent	-572	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3654796	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3149997	usd
CY2022Q4	us-gaap	Long Term Loans From Bank LongTermLoansFromBank	146253	usd
CY2021Q4	us-gaap	Long Term Loans From Bank LongTermLoansFromBank	150000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30580	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	146253	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	180580	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3801049	usd
CY2021Q4	us-gaap	Liabilities Liabilities	3330577	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	270307	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	270307	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	270307	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	270307	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	27	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	27	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	55000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	55000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32630506	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30921701	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32527172	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30818367	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	3263	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	3092	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	29355626	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	29172169	usd
CY2022Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	103334	shares
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	103334	shares
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1033	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1033	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-32426429	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-31697142	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	127675	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	127674	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2940871	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2395213	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	860178	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	935364	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1222989	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1392987	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	140644	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	134728	usd
CY2022	us-gaap	Gross Profit GrossProfit	1082345	usd
CY2021	us-gaap	Gross Profit GrossProfit	1258259	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15159	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	58232	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	66070	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1330627	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1612984	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	1388859	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	1694213	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-306514	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-435954	usd
CY2022	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	39563	usd
CY2021	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	31841	usd
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	52664	usd
CY2021	us-gaap	Interest Expense Other InterestExpenseOther	55970	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-964	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1684	usd
CY2021	VYCO	Forgiveness Of Debt Paycheck Protection Program ForgivenessOfDebtPaycheckProtectionProgram	117200	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-93191	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	27705	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-399705	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-408249	usd
CY2022	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-399705	usd
CY2021	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-408249	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-5212	usd
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-27413	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-404917	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-435662	usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	324370	usd
CY2021	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	324370	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-729287	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-760032	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-1	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-5	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-404916	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-435657	usd
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.01
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.01
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.00
CY2021	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.00
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31708076	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29627527	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-1981316	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	325131	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	21000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	5	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-760032	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2395213	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2395213	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	183628	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-729287	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-729287	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2940871	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2940871	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-404917	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-435662	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	11349	usd
CY2022	us-gaap	Depreciation Depreciation	61403	usd
CY2021	us-gaap	Depreciation Depreciation	57069	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	15515	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	12360	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	185610	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	341098	usd
CY2021	VYCO	Forgiveness Of Debt Paycheck Protection Program ForgivenessOfDebtPaycheckProtectionProgram	117200	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	30108	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-33142	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	56868	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	38785	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	14936	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-20034	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	39563	usd
CY2021	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	31841	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	52664	usd
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	51582	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-27676	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	48611	usd
CY2022	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-35607	usd
CY2021	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	9911	usd
CY2022	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-1659	usd
CY2021	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-3980	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-217016	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	21369	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2780	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	38375	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2780	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-38375	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	172500	usd
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	10000	usd
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	58600	usd
CY2022	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-6611	usd
CY2021	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-6655	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	165889	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	61945	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-53906	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	44939	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	90941	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	46002	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	37035	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	90941	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	8246	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	4386	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	3050	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	5032	usd
CY2022	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_801_eus-gaap--BasisOfAccounting_zoAn0M0nyV5b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_821_zGeSnUxBnGl1">BUSINESS OF THE COMPANY AND GOING CONCERN</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business Description</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vycor Medical, Inc. (the “Company”) designs, develops and markets neurological medical devices and therapies through two operating divisions: Vycor Medical and NovaVision. Vycor Medical focuses on brain and cervical surgical access systems for sale to hospitals and medical professionals; NovaVision focuses on neuro-stimulation therapies and diagnostic devices for the treatment and screening of vision field loss resulting from neurological damage.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Ability to continue as a Going Concern</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred losses since its inception, including a net loss of $<span id="xdx_901_eus-gaap--NetIncomeLoss_iN_di_c20220101__20221231_zWBI5crKnhNe" title="Net loss">404,917</span> and $<span id="xdx_90A_eus-gaap--NetIncomeLoss_iN_di_c20210101__20211231_zrenoIGEcCdd" title="Net loss">435,662</span> for the years ending December 31, 2022 and 2021 respectively and has not generated sufficient cash flows from operations. As at December 31, 2022 the Company had a working capital deficiency of $<span id="xdx_908_ecustom--WorkingCapitalDeficit_iI_pp0p0_c20221231_znRuv0cdzL1d" title="Working capital deficiency">551,433</span> excluding related party liabilities of $<span id="xdx_90E_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20221231_zsqEcEnCi89d" title="Related party liabilities">2,585,600</span>. As a result these conditions, among others, raise substantial doubt regarding our ability to continue as a going concern. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Company is executing on a plan to achieve a reduction in cash operating losses. Included within the working capital deficiency above is a term note for $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20221231__dei--LegalEntityAxis__custom--EuroAmericanInvestmentCorpMember_zeaBkVBIpQ58">300,000 </span>to EuroAmerican Investment Corp. (“EuroAmerican”), together with accrued interest of $<span id="xdx_909_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20221231__dei--LegalEntityAxis__custom--EuroAmericanInvestmentCorpMember_zggcnw3Bq7bl">424,897</span>, which has a maturity date of <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__dei--LegalEntityAxis__custom--EuroAmericanInvestmentCorpMember_zpgQwoWl0QIa" title="Maturity date">December 31, 2023</span>, having been extended on a number of occasions from its initial due date of June 11, 2011. At this time, it is not known whether any further extension of the note beyond December 31, 2023 will be available. However, the Company believes it may not have sufficient cash to meet its various cash needs through March 31, 2024 unless the Company is able to obtain additional cash from the issuance of debt or equity securities. Fountainhead, the Company’s largest shareholder, has provided working capital funding to the Company on an as-needed basis, although there is no guarantee that this will continue to be the case. The Company may consider seeking additional equity or debt funding, although there is no assurance that this would be available on acceptable terms or at all. If adequate funds are not available, the Company may have to delay or curtail development or commercialization of products or cease some of its operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-404917	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-435662	usd
CY2022Q4	VYCO	Working Capital Deficit WorkingCapitalDeficit	551433	usd
CY2022Q4	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	2585600	usd
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022	VYCO	Patient Deposits PatientDeposits	19154	usd
CY2021	VYCO	Patient Deposits PatientDeposits	30944	usd
CY2021	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	26545	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	5062	usd
CY2021	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	26545	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	-5062	usd
CY2021	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	-26545	usd
CY2022	VYCO	Provision For Inventory Obsolescence ProvisionForInventoryObsolescence	13160	usd
CY2021	VYCO	Provision For Inventory Obsolescence ProvisionForInventoryObsolescence	12360	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Foreign Currency Translation Gains Losses DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses	-150	usd
CY2021	us-gaap	Disposal Group Including Discontinued Operation Foreign Currency Translation Gains Losses DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses	-868	usd
CY2022	VYCO	Disposal Group Including Discontinued Operation Other Income Expense DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense	-150	usd
CY2021	VYCO	Disposal Group Including Discontinued Operation Other Income Expense DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense	-868	usd
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-5212	usd
CY2021	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-27413	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-5212	usd
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-27413	usd
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	150000	usd
CY2022	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P5Y
CY2022Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	0	usd
CY2021Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	0	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_840_eus-gaap--UseOfEstimates_zLAB2f3ogcUf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zbH8na7ICBK5">Uses of estimates in the preparation of financial statements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimated. To the extent management’s estimates prove to be incorrect, financial results for future periods may be adversely affected. Significant estimates and assumptions contained in the accompanying consolidated financial statements include management’s estimate of the allowance for uncollectible accounts receivable and provision for inventory obsolescence.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	46915	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30580	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	29591	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	77495	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	493373	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	320873	usd
CY2022Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	324711	usd
CY2021Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	319329	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	146253	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4723941	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4495369	shares
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	1212	usd
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	380	usd
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	1212	usd
CY2021Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	380	usd
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation AssetsOfDisposalGroupIncludingDiscontinuedOperation	1212	usd
CY2021Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation AssetsOfDisposalGroupIncludingDiscontinuedOperation	380	usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Accounts Payable Current DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent	693	usd
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation Accounts Payable Current DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent	4	usd
CY2022Q4	VYCO	Disposal Groups Including Discontinued Operation Other Current Liabilities DisposalGroupsIncludingDiscontinuedOperationOtherCurrentLiabilities	-2092	usd
CY2021Q4	VYCO	Disposal Groups Including Discontinued Operation Other Current Liabilities DisposalGroupsIncludingDiscontinuedOperationOtherCurrentLiabilities	-576	usd
CY2022Q4	VYCO	Liabilities Of Disposal Groups Including Discontinued Operation Current LiabilitiesOfDisposalGroupsIncludingDiscontinuedOperationCurrent	-1399	usd
CY2021Q4	VYCO	Liabilities Of Disposal Groups Including Discontinued Operation Current LiabilitiesOfDisposalGroupsIncludingDiscontinuedOperationCurrent	-572	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	5062	usd
CY2022Q4	us-gaap	Inventory Work In Process And Raw Materials InventoryWorkInProcessAndRawMaterials	109894	usd
CY2021Q4	us-gaap	Inventory Work In Process And Raw Materials InventoryWorkInProcessAndRawMaterials	77166	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	138980	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	130355	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	248874	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	207521	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	32645	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	79560	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	29591	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1222989	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1392987	usd
CY2022	us-gaap	Gross Profit GrossProfit	1082345	usd
CY2021	us-gaap	Gross Profit GrossProfit	1258259	usd
CY2022Q4	us-gaap	Assets Assets	860178	usd
CY2021Q4	us-gaap	Assets Assets	935364	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1222989	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1392987	usd
CY2022	us-gaap	Gross Profit GrossProfit	1082345	usd
CY2021	us-gaap	Gross Profit GrossProfit	1258259	usd
CY2022Q4	us-gaap	Assets Assets	860178	usd
CY2021Q4	us-gaap	Assets Assets	935364	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1389211	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1386431	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1085441	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1024038	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	303770	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	362393	usd
CY2022	us-gaap	Depreciation Depreciation	61403	usd
CY2021	us-gaap	Depreciation Depreciation	57069	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	11349	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	680000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.28
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	680000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.28
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-382553	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-398536	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-22364	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-37126	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-404917	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-435662	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-85033	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-91489	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-204	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-2684	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-85237	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-94173	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4672000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4511000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	1	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	1	pure
CY2022	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	The U.S. Tax Cuts and Jobs Act (Tax Act) was enacted on December 22, 2017 and introduces significant changes to U.S. income tax law. Effective in 2018, the Tax Act reduces the U.S. statutory tax rate from 35% to 21% and creates new taxes on certain foreign-sourced earnings and certain related-party payments, which are referred to as the global intangible low-taxed income tax and the base erosion tax, respectively.
CY2017Q4	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.155	pure
CY2017Q4	VYCO	Foreign Cash And Net Current Assets Percentage ForeignCashAndNetCurrentAssetsPercentage	0.08	pure
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	19881000	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	19058000	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.21	pure
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022	us-gaap	Payments For Rent PaymentsForRent	79314	usd
CY2021	us-gaap	Payments For Rent PaymentsForRent	79663	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	34384	usd
CY2012Q2	VYCO	Sales And Excise Tax Payable Reduction Current And Noncurrent SalesAndExciseTaxPayableReductionCurrentAndNoncurrent	75000	eur
CY2012Q2	VYCO	Sales And Excise Tax Payable Reduction Current And Noncurrent SalesAndExciseTaxPayableReductionCurrentAndNoncurrent	82000	usd
CY2012Q2	us-gaap	Interest Expense InterestExpense	12000	eur
CY2012Q2	us-gaap	Interest Expense InterestExpense	13200	usd
CY2016Q4	VYCO	Sales And Excise Tax Payable Reduction Current And Noncurrent SalesAndExciseTaxPayableReductionCurrentAndNoncurrent	75000	eur
CY2016Q4	VYCO	Sales And Excise Tax Payable Reduction Current And Noncurrent SalesAndExciseTaxPayableReductionCurrentAndNoncurrent	82000	usd
CY2016Q4	us-gaap	Interest Expense InterestExpense	12000	eur
CY2016Q4	us-gaap	Interest Expense InterestExpense	13200	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	39563	usd
CY2021	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	31841	usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	324370	usd
CY2021	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	324370	usd
CY2022	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	1946220	usd
CY2021	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	1621850	usd
CY2022	dei	Auditor Firm AuditorFirmId	273

Files In Submission

Name	View Source	Status
0001493152-23-012257-index-headers.html	Edgar Link	pending
0001493152-23-012257-index.html	Edgar Link	pending
0001493152-23-012257.txt	Edgar Link	pending
0001493152-23-012257-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
logo_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vyco-20221231.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
vyco-20221231_lab.xml	Edgar Link	unprocessable
vyco-20221231_def.xml	Edgar Link	unprocessable
vyco-20221231_cal.xml	Edgar Link	unprocessable
vyco-20221231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VYCO
Vycor Medical Inc Stock $vyco

2023 Q2 Form 10-K Financial Statement

#000149315223012257 Filed on April 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VYCO Vycor Medical Inc Stock $vyco

2023 Q2 Form 10-K Financial Statement

#000149315223012257 Filed on April 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VYCO
Vycor Medical Inc Stock $vyco